Atara Biotherapeutics (NASDAQ:ATRA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Atara Biotherapeutics (NASDAQ:ATRA) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02), FiscalAI reports. The firm had revenue of $1.22 million during the quarter, compared to the consensus estimate of $0.80 million.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ:ATRA traded down $0.19 during midday trading on Thursday, reaching $8.04. The company’s stock had a trading volume of 3,745 shares, compared to its average volume of 551,594. Atara Biotherapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $19.15. The firm has a 50 day moving average price of $9.01 and a two-hundred day moving average price of $7.82. The firm has a market capitalization of $80.72 million, a price-to-earnings ratio of -7.96 and a beta of 0.28.

Insider Buying and Selling at Atara Biotherapeutics

In related news, Director Brian Cherry purchased 104,166 shares of Atara Biotherapeutics stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $9.60 per share, for a total transaction of $999,993.60. Following the completion of the acquisition, the director owned 166,486 shares of the company’s stock, valued at $1,598,265.60. This trade represents a 167.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anhco Nguyen sold 5,062 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $8.08, for a total value of $40,900.96. Following the completion of the sale, the chief executive officer owned 132,775 shares of the company’s stock, valued at approximately $1,072,822. This represents a 3.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 41.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ATRA. Weiss Ratings raised shares of Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Wall Street Zen raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Finally, TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Atara Biotherapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient. Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo. The therapy is approved for certain adults and children with EBV-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation.